The CNPY2 (Canopy FGF Signaling Regulator 2) antibody is a research tool used to study the CNPY2 protein, a member of the conserved Canopy family implicated in cellular stress responses and protein quality control. CNPY2. also known as PRAT4B or C20orf31. is an endoplasmic reticulum (ER)-resident chaperone-like protein that interacts with unfolded protein response (UPR) mediators and modulates the stability or trafficking of membrane proteins, including Toll-like receptors (TLRs) and growth factor receptors. It plays roles in ER-associated degradation (ERAD), immune signaling, and cellular homeostasis. Dysregulation of CNPY2 has been linked to cancers, inflammatory diseases, and metabolic disorders. Antibodies targeting CNPY2 enable the detection and analysis of its expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These tools help elucidate CNPY2's involvement in pathological processes, such as tumor progression (e.g., promoting angiogenesis in glioblastoma) or metabolic dysfunction. Commercial CNPY2 antibodies are typically raised in rabbits or mice using immunogenic peptide sequences, with validation in specific applications. Research using CNPY2 antibodies contributes to understanding ER stress pathways and developing therapeutic strategies targeting UPR-related diseases.